LUPIN Lupin Q4 FY26 results (Jan–Mar 2026) and concall
Management summary
- Lupin delivered a strong Q4 and full fiscal year FY26, achieving record sales and profitability driven by robust growth across all key geographies, particularly the US and India.
- The company's strategic focus on complex products, biosimilars, and specialty segments is yielding results, with a significant increase in net cash.
- However, Q4 saw a sequential EBITDA decline due to one-off settlement costs and higher operating expenses, and the company anticipates a higher effective tax rate in FY27.
Source: Inve concall analysis and management guidance record.
Highlights
-
Total revenue from operations for Q4 FY26 was INR 7,475 crores, marking a 32% YoY growth and the 15th consecutive quarter of growth.
-
EBITDA for Q4 FY26 increased by 68% YoY to INR 2,171 crores, with the margin expanding by 620 basis points to 29.4%.
-
The US business achieved record sales of USD 1.3 billion for the full year FY26, representing an impressive 40% YoY growth, driven by new product launches like Tolvaptan and Mirabegron.
-
India's core prescription business grew 14.5% YoY in Q4 FY26, outperforming IPM growth by 1.3 times, with the chronic segment now accounting for 66% of the portfolio.
What they filed
Q4 FY26: revenue up 16.7%, net profit up 67.6% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 4,208 | 4,486 | 5,709 | 4,068 | 4,501 +7% | 5,235 +17% |
| EBITDA | 1,411 | 1,746 | 2,730 | 1,176 | 1,617 +15% | 2,282 +31% |
| Net profit | 985 | 1,291 | 2,128 | 1,357 | 717 −27% | 2,164 +68% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Guidance & targets
2Revenue
Overall Sales Growth Revenue · FY27 · High confidence high-single digits
Profitability
EBITDA Margin Profitability · FY27 · High confidence around 25%
Source: Inve Guidance Tracker — management targets and direct quotes from the earnings call transcript.
Q&A highlights
2FY27 Guidance - EBITDA margin impact from competition Direct
Yes, we have factored that in both competition for Mirabegron as well as Tolvaptan.
Clarifies the impact of anticipated competition on future profitability guidance, indicating a realistic outlook.
Asked by Tushar Manudhane
Q4 EBITDA decline QoQ despite revenue growth Direct
Essentially the EBITDA margins decline because of there's a slightly increased, manpower cost, as you can see. The second is essentially, we have captured what we have, paid out Astellas on account of Mirabegron settlement as part of the manufacturing other expenses line that's a
Explains the sequential margin compression, highlighting specific cost items and a settlement that impacted the quarter.
Asked by Tushar Manudhane
Unlock risks & concerns, Q1 FY27 watchlist, and full call analysis
You’re reading a preview. Opening the full call uses 1 concall credit and unlocks:
- 8 risks, concerns & management red flags
- 5 watchlist triggers for Q1 FY27
- +10 more guidance targets & verbatim management quotes
- +6 more analyst Q&A exchanges & evasion checks
- Capital allocation & full section-by-section narrative
Sign in to use your monthly call allowance.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared and our regulatory disclaimer. · Share on WhatsApp · Scorecard image





